Clinical trial
A Phase II Study of BVD-523 in Metastatic Uveal Melanoma
NCT03417739 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study of BVD-523 in Metastatic Uveal Melanoma
- Lead sponsor
- Dana-Farber Cancer Institute
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- March 26, 2018
- Completion date
- July 16, 2025
- Enrollment
- 13 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.